Mostrando 5,161 - 5,180 Resultados de 5,191 Para Buscar '"RBD"', tiempo de consulta: 0.21s Limitar resultados
  1. 5161
    “…SARS-CoV-2 memory CD4(+) T cells were strongly associated with both receptor binding domain (RBD)-specific memory B cells (r 0.87, p <0.0001) and SARS-CoV-2-specific memory CD8(+) T cells (r 0.48, p <0.0001). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine
  2. 5162
    “…BACKGROUND: ADG20 is a fully human IgG1 monoclonal antibody engineered to have high potency and broad neutralization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other SARS-like CoVs with pandemic potential by binding to a highly conserved epitope in the receptor-binding domain (RBD) of the spike protein. The Fc region of ADG20 has been modified to provide an extended half-life. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    633. Preliminary Results from a Phase 1 Single Ascending-Dose Study Assessing Safety, Serum Viral Neutralizing Antibody Titers (sVNA), and Pharmacokinetic (PK) Profile of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID-19)
  3. 5163
    “…Os níveis de anticorpos contra a porção RBD (Receptor Binding Domain) da proteína S foram detectados e quantificados utilizando o kit ACCESS SARS-CoV-2 IgG (1st IS) (Beckman Coulter, EUA). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    AVALIAÇÃO DA RESPOSTA VACINAL CONTRA SARS-COV-2 EM PACIENTES COM FIBRILAÇÃO ATRIAL ANTICOAGULADOS
  4. 5164
    “…The primary endpoint of the trial is to assess the rate of 2-fold antibody titre increase 14 days after vaccination measured by quantitative enzyme-linked immunosorbent assay (Anti-RBD-ELISA) against wild-type virus. Secondary endpoints include the changes in neutralising antibody titres (Virus Neutralisation Assay) against wild-type as well as against Variants of Concern (VOC) at 14 days and up to 12 months. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network
  5. 5165
    “…Essas amostras foram triadas para pesquisa de anticorpos IgG e IgM contra o epítopo RBD da proteína Spike do SARS-CoV-2 no Teste Rápido (TR) qualitativo Kit One Step COVID-2019 (CELER). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    FREQUÊNCIA DE TESTES RÁPIDOS POSITIVOS PARA SARS-COV-2 ENTRE DOADORES DE SANGUE
  6. 5166
    “…PURPOSE: Sotrovimab (VIR-7831), a human IgG1κ monoclonal antibody (mAb), binds to a conserved epitope on the SARS-CoV-2 spike protein receptor binding domain (RBD). The Fc region of VIR-7831 contains an LS modification to promote neonatal Fc receptor (FcRn)–mediated recycling and extend its serum half-life. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    In vivo biodistribution and pharmacokinetics of sotrovimab, a SARS-CoV-2 monoclonal antibody, in healthy cynomolgus monkeys
  7. 5167
    “…Specific ELIZA antibody response against a combination of S1 and RBD antigens 4 weeks after the second injection increased more than three times in the vaccine compared to the placebo group (GMR = 3.34, 95% CI 2.5–4.47, N:142). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18–70 years
  8. 5168
    por van Dam, Koos P. J., Volkers, Adriaan G., Wieske, Luuk, Stalman, Eileen W., Kummer, Laura Y. L., van Kempen, Zoé L. E., Killestein, Joep, Tas, Sander W., Boekel, Laura, Wolbink, Gerrit J., van der Kooi, Anneke J., Raaphorst, Joost, Takkenberg, R. Bart, D’Haens, Geert R. A. M., Spuls, Phyllis I., Bekkenk, Marcel W., Musters, Annelie H., Post, Nicoline F., Bosma, Angela L., Hilhorst, Marc L., Vegting, Yosta, Bemelman, Frederike J., Voskuyl, Alexandre E., Broens, Bo, Sanchez, Agner Parra, van Els, Cécile A. C. M., de Wit, Jelle, Rutgers, Abraham, de Leeuw, Karina, Horváth, Barbara, Verschuuren, Jan J. G. M., Ruiter, Annabel M., van Ouwerkerk, Lotte, van der Woude, Diane, Allaart, Renée C. F., Teng, Y. K. Onno, van Paassen, Pieter, Busch, Matthias H., Jallah, Papay B. P., Brusse, Esther, van Doorn, Pieter A., Baars, Adája E., Hijnen, Dirk Jan, Schreurs, Corine R. G., van der Pol, W. Ludo, Goedee, H. Stephan, Steenhuis, Maurice, Keijzer, Sofie, Keijser, Jim B. D., Cristianawati, Olvi, ten Brinke, Anja, Verstegen, Niels J. M., van Ham, S. Marieke, Rispens, Theo, Kuijpers, Taco W., Löwenberg, Mark, Eftimov, Filip
    Publicado 2023
    “…A serum sample was collected before first vaccination to measure SARS-CoV-2 anti-receptor-binding domain (RBD) antibodies. RESULTS: In total, 193 IMID patients on ISP and 113 controls were included. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity
  9. 5169
    “…Immunogenicity was assessed by measuring antibody titers against receptor-binding domain (RBD) of SARS-CoV-2 spike protein in all participants and neutralizing antibody titer in 100 participants per group. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Heterologous ChAdOx1 and Bnt162b2 vaccination induces strong neutralizing antibody responses against SARS-CoV-2 including delta variant with tolerable reactogenicity
  10. 5170
    “…Consistent with previous reports, risk factors and prodromal features associated with PD included traumatic brain injury, odds ratio (OR), 1.62; 95% CI, 1.36-1.92; alcohol misuse, OR, 1.32; 95% CI, 1.21-1.44; hypertension, OR, 1.29; 95% CI, 1.26-1.31; anosmia, OR, 2.16; 95% CI, 1.59-2.93; and parasomnias (including RBD), OR, 1.62; 95% CI, 1.42-1.84. In addition, there were associations with restless legs syndrome (OR, 4.19; 95% CI, 3.91-4.50), sleep apnea (OR, 1.45; 95% CI, 1.37-1.54), epilepsy (OR, 2.26; 95% CI, 2.07-2.46), migraine (OR, 1.21; 95% CI, 1.12-1.29), bipolar disorder (OR, 3.81; 95% CI, 3.11-4.67), and schizophrenia (OR, 4.48; 95% CI, 3.82-5.25). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Widening the Spectrum of Risk Factors, Comorbidities, and Prodromal Features of Parkinson Disease
  11. 5171
    “…METHODS: Final containers of IVIG/SCIG and CP donations were analyzed by commercial ELISA for anti-SARS-CoV-2 S1-receptor binding domain (RBD) IgG as well as microneutralization assay using a patient-derived SARS-CoV-2 (D614G) isolate. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin
  12. 5172
    “…METHODS: The synthetic consensus (SynCon®) sequence for INO-4802 SARS-CoV-2 spike with focused RBD changes and dual proline mutations was codon-optimized (Figure 1). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    579. Design and Immunogenicity of a Pan-SARS-CoV-2 Synthetic DNA Vaccine
  13. 5173
    “…TRIAL REGISTRATION: Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine; ClinicalTrial.gov NCT04833101.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial
  14. 5174
    “…The studies on the molecular mechanisms of EGCG in inhibition of SARS-CoV-2 infection in host cells reveal that EGCG blocks the entry of the virus particles by interaction with the receptor binding domain (RBD) of viral spike (S) protein to host cell surface receptor protease angiotensin-converting enzyme 2 (ACE2) as well as suppression of the expressions of host proteases, ACE2, TMPRSS2 and GRP78, required for viral entry, by Nrf2 activation in host cells. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Therapeutic potential of green tea catechin, (-)-epigallocatechin-3-O-gallate (EGCG) in SARS-CoV-2 infection: Major interactions with host/virus proteases
  15. 5175
    “…The Imperial Hybrid DABA, a two-step double antigen binding assay (DABA) for the detection and measurement of total antibody directed to the receptor binding domain (RBD) of SARS-CoV-2 was used for analysis. The cut-off (CO) for positivity is established by adding 0.1 to the average of optical density (OD) obtained for the negative controls. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Prevalence of Sars-Cov-2 Infection in Patients with Chronic Myeloid Leukemia
  16. 5176
    “…IgG antibodies to the receptor-binding domain (RBD) of the S1 subunit of the spike protein of SARS-CoV-2 were analyzed by SARS-CoV-2 IgG II Quant (Abbott, Ireland). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Response to BNT162b2 Sars-Cov-2 Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
  17. 5177
    “…The SARS-CoV-2 spike (S) protein is decorated with high mannose N-glycosites that are in close proximity to the viral receptor binding domain (RBD). Our goal was to use the H84T-BanLec as the extracellular targeting domain of a chimeric antigen receptor (CAR). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    CAR-NK Cells Targeting Sars-Cov-2 Glycosites As COVID-19 Treatment
  18. 5178
    por Valim, Valéria, Gouvea, Maria da Penha Gomes, Filho, Olindo Assis Martins, Carvalho, Andrea Teixeira, Camacho, Luiz Antônio Bastos, Villela, Daniel A. Maciel, Neto, Lauro Ferreira Pinto, Domingues, Carla, Moulaz, Isac Ribeiro, Thompson, Beatriz Paoli, Lança, Karen Evelin Monlevade, Lacerda, Gabriela Curto Cristianes, Lenzi, João Pedro Gonçalvez, Ramos, Sabrina de Souza, Miossi, João Pedro Moraes, Rassele, Matheus Leite, Pimentel, Felipe de Castro, Henriques, Allan Gonçalves, Amaral, Maria Eduarda Moraes Hibner, Silva, Lucas Santos, Pasti, Laís, Vieira, Gabriel Smith Sobral, Roza, Thais Luma de Oliveira, Ramos, Alessandro Demoner, Surlo, Heitor Filipe, Grillo, Luiza Lorenzoni, Aguiar, Laura Gonçalves Rodrigues, Rosi, Matheus Pereira, Rizzi, Ramon Borge, Athayde, Paula dos Santos, Lorencini, Pietra Zava, Silva, Adriana Santos, Reuter, Tania, Jubini, Jaquelini, Lyra, Danielle Grillo Pacheco, Rodrigues, Rodrigo Ribeiro, da Silva, Cristiano Soares, Reblin, Luís Carlos, Cardoso, Orlei, Miyamoto, Samira T., Machado, Ketty Lysie Libardi Lira, Forechi, Ludimila, Strauss, Carolina, Percio, Jadher, Barrera, Lely Stella Guzmán, Junior, Nésio Fernandes de Medeiros, Mill, José Geraldo
    Publicado 2022
    “…Foram estudados a incidência novos casos, número de mortes, internações e admissões em UTI, anticorpos neutralizantes por teste de neutralização em placa (PRNT) e quimioluminescência contra a porção RBD da fração S1 da proteína Spike, anticorpos totais IgG específico para SARS-Cov2, fatores solúveis sistêmicos, imunidade celular por estimulação antígeno-específica de células mononucleares do sangue periférico in vitro e investigação de Linfócitos T e B de memória e de citocinas intracitoplasmáticas. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    EFETIVIDADE, IMUNOGENICIDADE E SEGURANÇA DA MEIA DOSE DA VACINA CHADOX1 NCOV-19 CONTRA SARS-COV2 (PROJETO VIANA)
  19. 5179
    “…N-IgG (899 [82·0%]), S-IgG (1043 [95·2%]), RBD-IgG (1032 [94·2%]), and neutralising (115 [81·6%] of 141) antibodies were detectable 12 months after initial infection in most individuals. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study
  20. 5180
    “…METHODS: Specific anti-RBD (receptor-binding domain) titers against trimeric spike glycoprotein (S) of SARS-CoV-2 by Roche Elecsys Anti-SARS-CoV-2 S ECLIA immunoassay were determined in serum samples of 27 healthcare workers with a previously documented history of SARS-CoV-2 infection and 123 healthcare workers without, during antibody titers’ monitoring. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT – IRCCS “Fondazione Pascale” Cancer Center (Naples, Italy)
Herramientas de búsqueda: RSS